Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Consecutive lynestrenol and cross-sex hormone treatment in biological female adolescents with gender dysphoria: a retrospective analysis.

Tack LJ, Craen M, Dhondt K, Vanden Bossche H, Laridaen J, Cools M.

Biol Sex Differ. 2016 Feb 16;7:14. doi: 10.1186/s13293-016-0067-9. eCollection 2016.

2.

Gender identity disorder in twins: a review of the case report literature.

Heylens G, De Cuypere G, Zucker KJ, Schelfaut C, Elaut E, Vanden Bossche H, De Baere E, T'Sjoen G.

J Sex Med. 2012 Mar;9(3):751-7. doi: 10.1111/j.1743-6109.2011.02567.x. Epub 2011 Dec 6. Review.

PMID:
22146048
3.

Synthesis and in vitro and in vivo antifungal activity of the hydroxy metabolites of saperconazole.

Meerpoel L, Heeres J, Backx LJ, Van der Veken LJ, Hendrickx R, Corens D, De Groot A, Leurs S, Van der Eycken L, Weerts J, Luyts P, Van Gerven F, Woestenborghs FA, Van Breda A, Oris M, van Dorsselaer P, Willemsens GH, Bellens D, Marichal PJ, Vanden Bossche HF, Odds FC.

ChemMedChem. 2010 May 3;5(5):757-69. doi: 10.1002/cmdc.201000040.

PMID:
20379992
4.
5.

Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.

Meerpoel L, Backx LJ, Van der Veken LJ, Heeres J, Corens D, De Groot A, Odds FC, Van Gerven F, Woestenborghs FA, Van Breda A, Oris M, van Dorsselaer P, Willemsens GH, Vermuyten KJ, Marichal PJ, Vanden Bossche HF, Ausma J, Borgers M.

J Med Chem. 2005 Mar 24;48(6):2184-93.

PMID:
15771461
6.

The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis.

Vanden Bossche H, Ausma J, Bohets H, Vermuyten K, Willemsens G, Marichal P, Meerpoel L, Odds F, Borgers M.

Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.

7.

In vitro and in vivo activities of the novel azole antifungal agent r126638.

Odds F, Ausma J, Van Gerven F, Woestenborghs F, Meerpoel L, Heeres J, Vanden Bossche H, Borgers M.

Antimicrob Agents Chemother. 2004 Feb;48(2):388-91.

8.

Antifungal agents of use in animal health--practical applications.

Rochette F, Engelen M, Vanden Bossche H.

J Vet Pharmacol Ther. 2003 Feb;26(1):31-53. Review.

PMID:
12603775
9.

Antifungal agents of use in animal health--chemical, biochemical and pharmacological aspects.

Vanden Bossche H, Engelen M, Rochette F.

J Vet Pharmacol Ther. 2003 Feb;26(1):5-29. Review.

PMID:
12603774
10.

Genomic profiling of the response of Candida albicans to itraconazole treatment using a DNA microarray.

De Backer MD, Ilyina T, Ma XJ, Vandoninck S, Luyten WH, Vanden Bossche H.

Antimicrob Agents Chemother. 2001 Jun;45(6):1660-70.

11.

R115866 inhibits all-trans-retinoic acid metabolism and exerts retinoidal effects in rodents.

Stoppie P, Borgers M, Borghgraef P, Dillen L, Goossens J, Sanz G, Szel H, Van Hove C, Van Nyen G, Nobels G, Vanden Bossche H, Venet M, Willemsens G, Van Wauwe J.

J Pharmacol Exp Ther. 2000 Apr;293(1):304-12.

PMID:
10734183
12.

Accumulation of 3-ketosteroids induced by itraconazole in azole-resistant clinical Candida albicans isolates.

Marichal P, Gorrens J, Laurijssens L, Vermuyten K, Van Hove C, Le Jeune L, Verhasselt P, Sanglard D, Borgers M, Ramaekers FC, Odds F, Vanden Bossche H.

Antimicrob Agents Chemother. 1999 Nov;43(11):2663-70.

13.

Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans.

Marichal P, Koymans L, Willemsens S, Bellens D, Verhasselt P, Luyten W, Borgers M, Ramaekers FCS, Odds FC, Vanden Bossche H.

Microbiology. 1999 Oct;145 ( Pt 10):2701-2713. doi: 10.1099/00221287-145-10-2701.

PMID:
10537192
14.

Rhodamine 6G efflux for the detection of CDR1-overexpressing azole-resistant Candida albicans strains.

Maesaki S, Marichal P, Vanden Bossche H, Sanglard D, Kohno S.

J Antimicrob Chemother. 1999 Jul;44(1):27-31.

PMID:
10459807
15.

Synergic effects of tactolimus and azole antifungal agents against azole-resistant Candida albican strains.

Maesaki S, Marichal P, Hossain MA, Sanglard D, Vanden Bossche H, Kohno S.

J Antimicrob Chemother. 1998 Dec;42(6):747-53.

PMID:
10052898
16.

Antifungal drug resistance in pathogenic fungi.

Vanden Bossche H, Dromer F, Improvisi I, Lozano-Chiu M, Rex JH, Sanglard D.

Med Mycol. 1998;36 Suppl 1:119-28. Review.

PMID:
9988500
17.

Cytochromes P450 in fungi.

Vanden Bossche H, Koymans L.

Mycoses. 1998;41 Suppl 1:32-8. Review.

PMID:
9717384
18.

Azole antifungals: weak inhibitors of inducible nitric oxide synthase in mouse and human cells.

Vermuyten K, Laurijssens L, Vanden Bossche H.

Mycoses. 1997 Sep;40(3-4):119-25.

PMID:
9375500
19.

Molecular biological characterization of an azole-resistant Candida glabrata isolate.

Marichal P, Vanden Bossche H, Odds FC, Nobels G, Warnock DW, Timmerman V, Van Broeckhoven C, Fay S, Mose-Larsen P.

Antimicrob Agents Chemother. 1997 Oct;41(10):2229-37.

20.

Mechanisms of antifungal resistance.

Vanden Bossche H.

Rev Iberoam Micol. 1997 Jun;14(2):44-9.

21.

Hypothesis on the mechanism of resistance to fluconazole in Histoplasma capsulatum.

Wheat J, Marichal P, Vanden Bossche H, Le Monte A, Connolly P.

Antimicrob Agents Chemother. 1997 Feb;41(2):410-4.

22.

A molecular model for the interaction between vorozole and other non-steroidal inhibitors and human cytochrome P450 19 (P450 aromatase).

Koymans LM, Moereels H, Vanden Bossche H.

J Steroid Biochem Mol Biol. 1995 Jun;53(1-6):191-7.

PMID:
7626453
23.

Origin of differences in susceptibility of Candida krusei to azole antifungal agents.

Marichal P, Gorrens J, Coene MC, Le Jeune L, Vanden Bossche H.

Mycoses. 1995 Mar-Apr;38(3-4):111-7.

PMID:
7477085
24.

Mechanisms of resistance to azole antifungals.

Marichal P, Vanden Bossche H.

Acta Biochim Pol. 1995;42(4):509-16. Review.

25.

P450 inhibitors of use in medical treatment: focus on mechanisms of action.

Vanden Bossche H, Koymans L, Moereels H.

Pharmacol Ther. 1995;67(1):79-100. Review.

PMID:
7494862
26.

Molecular mechanisms of drug resistance in fungi.

Vanden Bossche H, Marichal P, Odds FC.

Trends Microbiol. 1994 Oct;2(10):393-400. Review.

PMID:
7850208
27.

Aromatase inhibitors--mechanisms for non-steroidal inhibitors.

Vanden Bossche HV, Moereels H, Koymans LM.

Breast Cancer Res Treat. 1994;30(1):43-55. Review.

PMID:
7949204
28.

Mechanisms and clinical impact of antifungal drug resistance.

Vanden Bossche H, Warnock DW, Dupont B, Kerridge D, Sen Gupta S, Improvisi L, Marichal P, Odds FC, Provost F, Ronin O.

J Med Vet Mycol. 1994;32 Suppl 1:189-202. Review. No abstract available.

PMID:
7722785
29.

Effects of itraconazole on cytochrome P-450-dependent sterol 14 alpha-demethylation and reduction of 3-ketosteroids in Cryptococcus neoformans.

Vanden Bossche H, Marichal P, Le Jeune L, Coene MC, Gorrens J, Cools W.

Antimicrob Agents Chemother. 1993 Oct;37(10):2101-5.

30.

Inhibitors of P450-dependent steroid biosynthesis: from research to medical treatment.

Vanden Bossche H.

J Steroid Biochem Mol Biol. 1992 Dec;43(8):1003-21. doi: 10.1016/0960-0760(92)90328-G.

PMID:
22217845
31.

Characterization of an azole-resistant Candida glabrata isolate.

vanden Bossche H, Marichal P, Odds FC, Le Jeune L, Coene MC.

Antimicrob Agents Chemother. 1992 Dec;36(12):2602-10.

32.

Ridogrel: a selective inhibitor of the cytochrome P450-dependent thromboxane synthesis.

Vanden Bossche H, Willemsens G, Bellens D, Janssen PA.

Biochem Pharmacol. 1992 Feb 18;43(4):739-44.

PMID:
1540227
33.

Molecular determinants of fungal dimorphism.

Vanden Bossche H, Kobayashi GS, Edman JC, Keath EJ, Maresca B, Soll DR.

J Med Vet Mycol. 1992;30 Suppl 1:73-6. No abstract available.

PMID:
1474461
35.

Mode of action of anti-Candida drugs: focus on terconazole and other ergosterol biosynthesis inhibitors.

Vanden Bossche H, Marichal P.

Am J Obstet Gynecol. 1991 Oct;165(4 Pt 2):1193-9.

PMID:
1951574
36.

Lipid-itraconazole interaction in lipid model membranes.

Brasseur R, Goormaghtigh E, Ruysschaert JM, Duquenoy PH, Marichal P, Vanden Bossche H.

J Pharm Pharmacol. 1991 Mar;43(3):167-71.

PMID:
1675272
37.

New non-steroidal aromatase inhibitors: focus on R76713.

De Coster R, Wouters W, Bowden CR, Vanden Bossche H, Bruynseels J, Tuman RW, Van Ginckel R, Snoeck E, Van Peer A, Janssen PA.

J Steroid Biochem Mol Biol. 1990 Nov 20;37(3):335-41. Review.

PMID:
2257238
38.

R 76713 and enantiomers: selective, nonsteroidal inhibitors of the cytochrome P450-dependent oestrogen synthesis.

Vanden Bossche H, Willemsens G, Roels I, Bellens D, Moereels H, Coene MC, Le Jeune L, Lauwers W, Janssen PA.

Biochem Pharmacol. 1990 Oct 15;40(8):1707-18.

PMID:
2242008
39.

Biochemical basis for the activity and selectivity of oral antifungal drugs.

Vanden Bossche H, Marichal P, Gorrens J, Coene MC.

Br J Clin Pract Suppl. 1990 Sep;71:41-6. Review.

PMID:
2091733
40.

Saperconazole: a selective inhibitor of the cytochrome P-450-dependent ergosterol synthesis in Candida albicans, Aspergillus fumigatus and Trichophyton mentagrophytes.

Vanden Bossche H, Marichal P, Willemsens G, Bellens D, Gorrens J, Roels I, Coene MC, Le Jeune L, Janssen PA.

Mycoses. 1990 Jul-Aug;33(7-8):335-52.

PMID:
2090934
41.

Mutation in cytochrome P-450-dependent 14 alpha-demethylase results in decreased affinity for azole antifungals.

Vanden Bossche H, Marichal P, Gorrens J, Bellens D, Moereels H, Janssen PA.

Biochem Soc Trans. 1990 Feb;18(1):56-9. Review. No abstract available.

PMID:
2185088
42.

From 14 alpha-demethylase inhibitors in fungal cells to androgen and oestrogen biosynthesis inhibitors in mammalian cells.

Vanden Bossche H, Willemsens G, Bellens D, Roels I, Janssen PA.

Biochem Soc Trans. 1990 Feb;18(1):10-3. Review. No abstract available.

PMID:
2185065
43.
44.

The role of cytochrome P-450 in dermatology.

Janssen PA, Vanden Bossche HF, Van Wauwe JP, Cauwenbergh GF, Degreef HJ.

Int J Dermatol. 1989 Oct;28(8):493-6. Review. No abstract available.

PMID:
2684875
45.

Terconazole. Pharmacology of a new antimycotic agent.

Cauwenbergh G, Vanden Bossche H.

J Reprod Med. 1989 Aug;34(8 Suppl):588-92. Review.

PMID:
2677363
46.

Perturbation of sterol biosynthesis by itraconazole and ketoconazole in Leishmania mexicana mexicana infected macrophages.

Hart DT, Lauwers WJ, Willemsens G, Vanden Bossche H, Opperdoes FR.

Mol Biochem Parasitol. 1989 Mar 1;33(2):123-34.

PMID:
2542790
47.

Biochemical approaches to selective antifungal activity. Focus on azole antifungals.

Vanden Bossche H, Marichal P, Gorrens J, Coene MC, Willemsens G, Bellens D, Roels I, Moereels H, Janssen PA.

Mycoses. 1989;32 Suppl 1:35-52. Review.

PMID:
2561184
48.

Selective inhibition of 14 alpha-desmethyl sterol synthesis in Candida albicans by terconazole, a new triazole antimycotic.

Isaacson DM, Tolman EL, Tobia AJ, Rosenthale ME, McGuire JL, Vanden Bossche H, Janssen PA.

J Antimicrob Chemother. 1988 Mar;21(3):333-43.

PMID:
3129389
49.

Cytochrome-P-450-dependent metabolism of retinoic acid in rat skin microsomes: inhibition by ketoconazole.

Vanden Bossche H, Willemsens G, Janssen PA.

Skin Pharmacol. 1988;1(3):176-85.

PMID:
2856164
50.

Mode of action studies. Basis for the search of new antifungal drugs.

Vanden Bossche H, Marichal P, Gorrens J, Geerts H, Janssen PA.

Ann N Y Acad Sci. 1988;544:191-207. No abstract available.

PMID:
2850749

Supplemental Content

Loading ...
Support Center